You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News items for the in vitro diagnostics industry for the week of June 29, 2020.
Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.
The technology from Scanwell is also being used for its at-home SARS-CoV-2 antibody test, which is under development and awaiting Emergency Use Authorization.
Some parts of Europe turned to serology testing early to try to get a handle on the pandemic but had to quickly pull back after those tests performed abysmally.
FIND will use the funding to support the development of rapid tests, especially in low- and middle-income countries.
The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
FIND and WHO are collaborating again, this time to to perform a standardized evaluation of currently available immunoassays.
Some believe that more could be done to help deliver diagnostics to the European market.
The two organizations are collaborating to perform a standardized evaluation of currently available molecular diagnostic tests to assess test performance.
Initially, FIND and the WHO will work to develop national essential diagnostics lists, as well as to collect data to support countries in their aim to provide universal health coverage.